Drugs / Humira
Humira cost
adalimumab · AbbVie. Every official price for Humira, side by side, with who pays it.
Short answer
We found no list price published by AbbVie. Pharmacies paid an average of $3,366.95–$6,735.20 per pen or syringe (NADAC, Oct 21, 2026). With the pharmacy coupon on TrumpRx.gov, Humira is $950 for 2 pens or syringes (paying without insurance). In 2024, Medicare Part D spent $5.7 billion on Humira, an average of $8,766.28 per prescription fill before rebates (CMS). In Medicare Part D, the yearly out-of-pocket limit is $2,100 in 2026 and $2,400 in 2027.145723
Source: CMS, data.medicaid.gov (NADAC) and Medicare.gov · checked Nov 15, 2026
Humira: the official numbers, by situation
| Price | Amount | Whose price, and who it applies to | Date |
|---|---|---|---|
| List price | Not published | We found no list price published by AbbVie. | — |
| TrumpRx.gov cash price Pen 40/0.4 mg/mL, qty 2 | $950.004 | Pharmacy coupon. Paying without insurance. | Nov 15, 2026 |
| TrumpRx.gov cash price Prefilled Syringe 10/0.1 mg/mL, qty 2 | $950.005 | Pharmacy coupon. Paying without insurance. | Nov 15, 2026 |
| Pharmacy cost (NADAC) per pen or syringe; a month depends on your dose | $3,366.95–$6,735.201 | What pharmacies pay on average (CMS survey). Not a patient price. | Oct 21, 2026 |
On Medicare drug coverage: 1,248 of 5,492 Part D plans list Humira for 2027 (23%), and 100% of those require prior authorization, in CMS's formulary file published Oct 15, 2026.13 By year and tier
None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.
FDA approval
- Humira (adalimumab) was first approved by the FDA on Dec 31, 2002, under application BLA125057.6
Every official price
| Price | Amount | What it is | Date |
|---|---|---|---|
| Maker's list price (WAC) | Not published | We found no current list price on AbbVie's own pages, so we do not show one. | — |
| Pharmacy acquisition cost (NADAC) Humira 40 mg/0.8 mL syringe | $3,368.961 | Per tablet or capsule in the pack. The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Humira pen 40 mg/0.8 mL | $3,366.951 | Per tablet or capsule in the pack. The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Humira(CF) 40 mg/0.4 mL syringe | $3,368.441 | Per tablet or capsule in the pack. The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Humira(CF) pen 40 mg/0.4 mL | $3,367.851 | Per tablet or capsule in the pack. The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Humira(CF) pen 80 mg/0.8 mL | $6,735.201 | Per tablet or capsule in the pack. The national average price pharmacies pay to buy it. | Oct 21, 2026 |
These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below.
Humira on TrumpRx.gov
| Listing | How sold | TrumpRx price | Options (as listed) | Checked |
|---|---|---|---|---|
| Humira® Pen | Pharmacy coupon | $950.004 | Pen 40/0.4 mg/mL, qty 2: $950.00 | Nov 15, 2026 |
| Humira® Prefilled Syringe | Pharmacy coupon | $950.005 | Prefilled Syringe 10/0.1 mg/mL, qty 2: $950.00 Prefilled Syringe 20/0.2 mg/mL, qty 2: $950.00 Prefilled Syringe 40/0.4 mg/mL, qty 2: $950.00 | Nov 15, 2026 |
Pharmacy coupon: shown at a pharmacy; the pharmacy confirms the final price. Cash prices; they don't go through insurance. Every TrumpRx price.
What Medicare spent on Humira in 2024
CMS publishes what Part D spent on each drug each year. Its spending is the gross drug cost, which includes what Medicare, the plan and the patient paid,8 and it does not reflect manufacturers' rebates.9 CMS lists Humira in 6 rows; together they come to $5.7 billion over 652,028 prescription fills, $8,766.28 per fill.
Medicare Part D, calendar year 2024 (CMS Medicare Part D Spending by Drug, checked Nov 15, 2026).
| Product (as CMS lists it) | Total spending | Fills | People | Per fill | Per person |
|---|---|---|---|---|---|
| Humira | $208.9 million7 | 25,521 | 3,912 | $8,185.6210 | $53,401.1111 |
| Humira Pen | $697.4 million7 | 85,167 | 11,719 | $8,188.6810 | $59,510.6411 |
| Humira(Cf) | $400.9 million7 | 46,620 | 6,661 | $8,599.3210 | $60,186.2311 |
| Humira(Cf) Pen | $4.3 billion7 | 490,303 | 63,768 | $8,828.6210 | $67,881.9911 |
| Humira(Cf) Pen Crohn'S-Uc-Hs | $59.2 million7 | 2,890 | 2,792 | $20,489.9310 | $21,209.1311 |
| Humira(Cf) Pen Psor-Uv-Adol Hs | $20.7 million7 | 1,527 | 1,497 | $13,580.5210 | $13,852.6811 |
These are totals and averages across everyone in Medicare who used the drug, not a price for one person. Averages per person depend on how long and how much each person used it.
How many Medicare Part D plans list Humira
Every Medicare drug plan in CMS's formulary file (standalone drug plans and Medicare Advantage plans with drug coverage). A plan counts when its drug list has at least one form or strength. Matched by RxNorm code and checked against the FDA NDC Directory. Plan counts, not people; to see your own plan's rules use Medicare Plan Finder.
| Plan year | What | Plans that list it | Prior auth. | Step therapy | Quantity limit | Lowest tier (plans) |
|---|---|---|---|---|---|---|
| 2026 | Humira (brand) | 2,901 of 5,49612 53% | 2,901 | 0 | 2,751 | tier 1: 91 · tier 2: 1 · tier 4: 46 · tier 5: 2,763 |
| 2026 | Any adalimumab biosimilar | 5,466 of 5,49612 99% | 5,344 | 0 | 5,159 | tier 1: 161 · tier 2: 2 · tier 3: 144 · tier 4: 50 · tier 5: 5,109 |
| 2026 | Humira or a biosimilar | 5,496 of 5,49612 100% | 5,374 | 0 | 5,189 | tier 1: 161 · tier 2: 2 · tier 3: 144 · tier 4: 50 · tier 5: 5,139 |
| 2027 | Humira (brand) | 1,248 of 5,49213 23% | 1,248 | 0 | 1,131 | tier 1: 31 · tier 4: 40 · tier 5: 1,177 |
| 2027 | Any adalimumab biosimilar | 5,492 of 5,49213 100% | 5,373 | 0 | 5,240 | tier 1: 123 · tier 2: 1 · tier 3: 756 · tier 4: 190 · tier 5: 4,422 |
| 2027 | Humira or a biosimilar | 5,492 of 5,49213 100% | 5,373 | 0 | 5,240 | tier 1: 123 · tier 2: 1 · tier 3: 756 · tier 4: 190 · tier 5: 4,422 |
Being on a plan's list is not a price: what you pay depends on the tier and your plan. Each plan can divide its tiers in different ways. What prior authorization, step therapy and tiers mean.
Humira and its biosimilars: what pharmacies pay (NADAC)
Each product's newest rate in our archived NADAC queries (newest weekly file Nov 11, 2026). Per pen or syringe. Not a patient price; a biosimilar is a separate product, and switching is a decision for you and your prescriber.
| Product (NADAC description) | Per pen or syringe | Rate effective |
|---|---|---|
| HUMIRA PEN 40 MG/0.8 ML | $3,366.9514 | Oct 21, 2026 |
| HUMIRA(CF) PEN 40 MG/0.4 ML | $3,367.8514 | Oct 21, 2026 |
| HUMIRA(CF) 40 MG/0.4 ML SYRINGE | $3,368.4414 | Oct 21, 2026 |
| HUMIRA 40 MG/0.8 ML SYRINGE | $3,368.9614 | Oct 21, 2026 |
| HUMIRA(CF) PEN 80 MG/0.8 ML | $6,735.2014 | Oct 21, 2026 |
| SIMLANDI(CF) 40 MG/0.4 ML SYRINGE | $478.6518 | Aug 19, 2026 |
| ADALIMUMAB-AATY(CF) 40 MG/0.4 ML SYRINGE | $489.0915 | Oct 21, 2026 |
| ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR | $490.68–$499.1715 | Oct 21, 2026 |
| HADLIMA 40 MG/0.8 ML SYRINGE | $493.7116 | Oct 21, 2026 |
| SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR | $499.2518 | Oct 21, 2026 |
| HADLIMA(CF) 40 MG/0.4 ML SYRINGE | $503.2416 | Oct 21, 2026 |
| HADLIMA(CF) PUSHTOUCH 40 MG/0.4 ML | $503.7816 | Oct 21, 2026 |
| HADLIMA PUSHTOUCH 40 MG/0.8 ML | $506.3816 | Oct 21, 2026 |
| ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML | $635.7615 | Oct 21, 2026 |
| ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML | $638.9815 | Oct 21, 2026 |
| ADALIMUMAB-ADBM(CF) PEN 40 MG/0.8 ML | $639.4115 | Oct 21, 2026 |
| ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK) | $872.6415 | Oct 21, 2026 |
| YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR | $896.51–$912.2117 | Oct 21, 2026 |
With Medicare
- What you pay depends on your Part D plan. The rules that apply to every Part D drug, from the deductible to the $2,400 out-of-pocket limit in 2027, Extra Help and the Medicare Prescription Payment Plan, are on one page: Part D costs · payment plan. Free one-on-one help: a SHIP counselor or 1-800-MEDICARE.
With commercial insurance or no insurance
- What you pay depends on your plan's copay or coinsurance. The maker lists its savings and support options here: AbbVie: Humira. We link to it but do not copy its terms.
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Get an email when a price or rule changes
Only when an official GLP-1 self-pay price or a Medicare or Medicaid rule changes, at most once a week, with the official source for every change.
Official sources for this page (20)
- data.medicaid.gov: NADAC (National Average Drug Acquisition Cost) 2026 · as of Oct 23, 2026
“Out-of-pocket limit Yearly $2,100 (in 2026).”
Medicare.gov: Medicare costs · as of Oct 23, 2026“Out-of-Pocket Threshold: $2,100 Out-of-Pocket Threshold: $2,400”
CMS: CY 2027 Medicare Advantage and Part D Rate Announcement (Table V-6) · as of Oct 23, 2026- TrumpRx.gov: Humira® Pen listing · as of Nov 15, 2026
- TrumpRx.gov: Humira® Prefilled Syringe listing · as of Nov 15, 2026
“BLA125057 ORIG-1 approved 20021231”
FDA (Drugs@FDA via openFDA): BLA125057 · as of Nov 15, 2026“Humira: Tot_Spndng_2024 208905154.75, Tot_Clms_2024 25521, Tot_Benes_2024 3912; Humira Pen: Tot_Spndng_2024 697405207.41, Tot_Clms_2024 85167, Tot_Benes_2024 11719; Humira(Cf): Tot_Spndng_2024 400900510.75, Tot_Clms_2024 46620, Tot_Benes_2024 6661; Humira(Cf) Pen: Tot_Spndng_2024 4328698864.2, Tot_Clms_2024 490303, Tot_Benes_2024 63768; Humira(Cf) Pen Crohn'S-Uc-Hs: Tot_Spndng_2024 59215904.35, Tot_Clms_2024 2890, Tot_Benes_2024 2792; Humira(Cf) Pen Psor-Uv-Adol Hs: Tot_Spndng_2024 20737458.22, Tot_Clms_2024 1527, Tot_Benes_2024 1497”
CMS: Medicare Part D Spending by Drug, 2024 (data.cms.gov) · as of Nov 15, 2026“Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”
CMS: Medicare Part D Spending by Drug (about the data) · as of Nov 15, 2026“The Part D spending metrics do not reflect any manufacturers' rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”
CMS: Medicare Part D Spending by Drug (about the data) · as of Nov 15, 2026“Part D drug spending divided by the number of prescription fills.”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026“Total Part D drug spending divided by the number of unique beneficiaries utilizing the drug during the benefit year.”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026- CMS: 2026_20260916.zip (Part D formulary file for 2026 plans, published 2026-09-23) · as of Nov 15, 2026
- CMS: 2027_20261008.zip (Part D formulary file for 2027 plans, published 2026-10-15) · as of Nov 15, 2026
- data.medicaid.gov: NADAC 2026, products named HUMIRA* · as of Oct 23, 2026
- data.medicaid.gov: NADAC 2026, products named ADALIMUMAB* · as of Nov 15, 2026
- data.medicaid.gov: NADAC 2026, products named HADLIMA* · as of Nov 15, 2026
- data.medicaid.gov: NADAC 2026, products named YUFLYMA* · as of Nov 15, 2026
- data.medicaid.gov: NADAC 2026, products named SIMLANDI* · as of Nov 15, 2026
- data.medicaid.gov: NADAC 2026, products named CYLTEZO* · as of Nov 15, 2026
- data.medicaid.gov: NADAC 2026, products named YUSIMRY* · as of Nov 15, 2026